Slide 1: Third Quarter 2024 in Review
Exhibit 99.2 NOVEMBER 4, 2024 GLAUKOS CORPORATION (NYSE: GKOS) THIRD QUARTER 2024 IN REVIEW Important Information This document is intended to be read by investors in advance of regularly scheduled quarterly conference calls and was designed to provide a review of Glaukos Corporation’s recent financ
Slide 2: Third Quarter 2024 Financial Results Summary
NOVEMBER 4, 2024 THIRD QUARTER 2024 FINANCIAL RESULTS SUMMARY Ophthalmic pharmaceutical and medical technology company Business focused on developing and commercializing novel, dropless platform Description therapies designed to disrupt the conventional standard of care and improve outcomes for pati
Slide 3: Revenue Performance & Commercial Overview
NOVEMBER 4, 2024 Revenue Performance & Commercial Overview Global Consolidated Revenue Performance Glaukos reported record third quarter net revenues of $96.7 million that were up 24% versus 3Q 2023. Our third quarter performance reflected continued solid execution across our global Glaucoma and Cor
Slide 4: U.S. Glaucoma
NOVEMBER 4, 2024 U.S. Glaucoma Our third quarter U.S. Glaucoma net revenues were approximately $51.6 million, representing year-over-year growth of 35% versus 3Q 2023 driven by early but growing contributions from iDose® TR, along with continued strong growth within our overall iStent® portfolio, le
Slide 5: Additional Commercial Updates & Commentary
NOVEMBER 4, 2024 Additional Commercial Updates & Commentary We have had several additional positive commercial updates worth highlighting here: ✓ Advanced commercial launch activities in the U.S. for iStent infinite in the third quarter of 2024 o Interventional glaucoma education efforts and improve
Slide 6: Slide 6
Slide 7: CMS Final Rules for Calendar Year 2025
NOVEMBER 4, 2024 ✓ CMS’s Final Rules for Calendar Year 2025 – Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Facility Fee Schedule updates: o APC assignment for standalone trabecular bypass procedures, CPT 0671T, finalized to remain in APC 5493 (unchanged
Slide 8: 2024 Revenue Guidance Raised to Reflect Strong Continued Momentum
NOVEMBER 4, 2024 2024 Revenue Guidance Raised to Reflect Strong Continued Momentum Glaukos now expects full-year 2024 global consolidated net sales of $377 - $379 million, up from its previous guidance of $370 - $376 million. This upwardly revised guidance attempts to take into consideration: ● Pote
Slide 9: Research & Development / Pipeline Overview
NOVEMBER 4, 2024 Research & Development / Pipeline Overview Pipeline Summary Our five key dropless technology therapy platforms designed to disrupt traditional treatment paradigms and generate cascades of future innovation are as follows: ● iStent® micro-scale surgical devices ● iDose® sustained-rel
Slide 10: Key R&D and Pipeline Updates
NOVEMBER 4, 2024 Key R&D and Pipeline Updates We are continuing to prudently invest in and advance our fulsome pipeline of core novel platforms, supported by more than $600 million of investment into our R&D programs since 2018 alone. Recent updates in our pipeline include: ✓ Announced positive topl
Slide 11: Product / Pipeline Chart
NOVEMBER 4, 2024 Product / Pipeline Chart 10
Slide 12: Other Financial Performance Overview
NOVEMBER 4, 2024 Other Financial Performance Overview As a reminder, we discuss our financial performance on a non-GAAP basis and summarize our GAAP performance. We encourage investors to review our GAAP to non-GAAP reconciliation which can be found in our earnings press release, the Additional Info
Slide 13: 11
11
Slide 14: Other Important Updates
NOVEMBER 4, 2024 Other Important Updates Ø On October 4, 2024, we issued a notice of redemption for the remaining $57.5 million in principal amount outstanding of our convertible senior notes due 2027. Pursuant to the notice, we anticipate these notes to convert to common stock before the redemption
Slide 15: Additional Information
NOVEMBER 4, 2024 Additional Information
Slide 16: 13
13
Slide 17: Forward-Looking Statements
NOVEMBER 4, 2024 Forward-Looking Statements This communication contains “forward-looking statements” within the meaning of federal securities laws. All statements other than statements of historical facts included in this presentation that address activities, events or developments that we expect, b
Slide 18: 14
14
Slide 19: Statement Regarding Use of Non-GAAP Financial Measures
NOVEMBER 4, 2024 Statement Regarding Use of Non-GAAP Financial Measures To supplement the consolidated financial results prepared in accordance with Generally Accepted Accounting Principles ("GAAP"), the Company uses certain non-GAAP historical financial measures. Management makes adjustments to the
Slide 20: GAAP Income Statement
NOVEMBER 4, 2024 GAAP Income Statement GLAUKOS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (in thousands, except per share amounts) Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Net sales $ 96,670 $ 78,048 $ 277,982 $ 232,346 Cost of
Slide 21: GAAP Balance Sheet
NOVEMBER 4, 2024 GAAP Balance Sheet GLAUKOS CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except par values) September 30, December 31, 2024 2023 (unaudited) Assets Current assets: Cash and cash equivalents $ 100,143 $ 93,467 Short-term investments 162,330 201,964 Accounts receiva
Slide 22: Slide 22
Slide 23: Primary GAAP to Non-GAAP Reconciliations
NOVEMBER 4, 2024 Primary GAAP to Non-GAAP Reconciliations GLAUKOS CORPORATION GAAP to Non-GAAP Reconciliations (in thousands, except per share amounts and percentage data) (unaudited) Q3 2024 Q3 2023 GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP Cost of sales $ 22,584 $ (5,523)(a) $ 17,061 $ 1
Slide 24: Primary GAAP to Non-GAAP Reconciliations
NOVEMBER 4, 2024 Primary GAAP to Non-GAAP Reconciliations GLAUKOS CORPORATION GAAP to Non-GAAP Reconciliations (in thousands, except per share amounts and percentage data) (unaudited) Year-to-Date Q3 2024 Year-to-Date Q3 2023 GAAP Adjustments Non-GAAP GAAP Adjustments Non-GAAP Cost of sales $ 65,392
Slide 25: Additional GAAP to Non-GAAP Reconciliations
NOVEMBER 4, 2024 Additional GAAP to Non-GAAP Reconciliations Reported Sales vs. Prior Periods (in thousands) Year-over-Year Percent Change Quarter-over-Quarter Percent Change 3Q 2024 3Q 2023 2Q 2024 Reported Operations (1) Currency (2) Reported Operations (1) Currency (2) International Glaucoma $24,